Immunic Inc (IMUX) FinancialsIMUXImmunic Inc

Evaluating the bottom line, Immunic, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -138.17%, provide a clear picture of how effectively IMUX converts its operational activities into shareholder value.

In the context of the broader market, IMUX competes directly with industry leaders such as IPHA and DERM. With a market capitalization of $219.13M, it holds a leading position in the sector. When comparing efficiency, IMUX's gross margin of N/A stands against IPHA's 3.59% and DERM's 61.58%. Such benchmarking helps identify whether Immunic, Inc. is trading at a premium or discount relative to its financial performance.

Immunic has reported substantial net losses in recent quarters, with Q2 2026 showing a net loss of $34,099,000. The company has a negative EPS of -0.80 for the latest quarter, indicating ongoing challenges in achieving profitability.